Compare Stocks: IBIO, SABS, BCYC, and ACIU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.50	$2.64	$2.10 ▼ $4.00	$254.44M	1.56	204,461 shs	271,324 shs
BCYC Bicycle Therapeutics	$3.89	$3.96	$3.33 ▼ $9.10	$272.27M	1.68	483,646 shs	300,617 shs
IBIO iBio	$0.87	$1.29	$0.78 ▼ $3.82	$56.01M	1.26	825,311 shs	1.64 million shs
SABS SAB Biotherapeutics	$2.98	$3.53	$2.10 ▼ $5.15	$271.15M	0.58	746,692 shs	659,610 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-8.09%	-9.42%	+2.04%	-29.58%
BCYC Bicycle Therapeutics	0.00%	+15.09%	+0.78%	-10.57%	-53.25%
IBIO iBio	0.00%	-22.58%	-27.72%	-39.93%	+87,099,900.00%
SABS SAB Biotherapeutics	0.00%	0.00%	-12.61%	-20.11%	+30.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.50	$2.64	$2.10 ▼ $4.00	$254.44M	1.56	204,461 shs	271,324 shs
BCYC Bicycle Therapeutics	$3.89	$3.96	$3.33 ▼ $9.10	$272.27M	1.68	483,646 shs	300,617 shs
IBIO iBio	$0.87	$1.29	$0.78 ▼ $3.82	$56.01M	1.26	825,311 shs	1.64 million shs
SABS SAB Biotherapeutics	$2.98	$3.53	$2.10 ▼ $5.15	$271.15M	0.58	746,692 shs	659,610 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-8.09%	-9.42%	+2.04%	-29.58%
BCYC Bicycle Therapeutics	0.00%	+15.09%	+0.78%	-10.57%	-53.25%
IBIO iBio	0.00%	-22.58%	-27.72%	-39.93%	+87,099,900.00%
SABS SAB Biotherapeutics	0.00%	0.00%	-12.61%	-20.11%	+30.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.80	Moderate Buy	$7.50	200.00% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	256.22% Upside
IBIO iBio	3.11	Buy	$5.29	506.86% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	302.68% Upside

Current Analyst Ratings Breakdown

Latest IBIO, SABS, BCYC, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/29/2026	ACIU AC Immune	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/24/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$17.51M	14.53	N/A	N/A	$0.54 per share	4.63
BCYC Bicycle Therapeutics	$61.21M	4.45	N/A	N/A	$8.79 per share	0.44
IBIO iBio	$100K	560.14	N/A	N/A	$1.54 per share	0.57
SABS SAB Biotherapeutics	$1.32M	205.42	$0.34 per share	8.72	$3.18 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.54	N/A	14.71	N/A	-245.32%	-100.17%	-28.36%	11/3/2026 (Estimated)
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest IBIO, SABS, BCYC, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ACIU AC Immune	-$0.22	N/A	N/A	N/A	$0.33 million	N/A
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	N/A	N/A	N/A	$12.22 million	N/A
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/6/2026	Q2 2026	ACIU AC Immune	-$0.1044	$0.03	+$0.1344	$0.0250	$9.59 million	$18.67 million
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.93	N/A
BCYC Bicycle Therapeutics	N/A	12.08	12.08
IBIO iBio	N/A	7.85	7.85
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
BCYC Bicycle Therapeutics	86.15%
IBIO iBio	7.90%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
BCYC Bicycle Therapeutics	22.00%
IBIO iBio	1.55%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	106	101.77 million	97.09 million	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Not Optionable

IBIO, SABS, BCYC, and ACIU Headlines

Recent News About These Companies

Contrasting SAB Biotherapeutics (NASDAQ:SABS) and Veracyte (NASDAQ:VCYT)

October 6, 2026 | americanbankingnews.com

SAB Biotherapeutics, Inc. Announces Presentations Featuring SAB-142 Phase 1 Data At Breakthrough T1D Clinical & Research Congress

October 1, 2026 | marketscreener.comM

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

October 1, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated "Moderate Buy" by Sell-Side Analysts

September 30, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 2.4% - Here's What Happened

September 28, 2026 | marketbeat.com

SAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of Diabetes

September 22, 2026 | marketscreener.comM

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

SAB BIO to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

SAB Biotherapeutics Inc SABS

May 20, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, SABS, BCYC, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

$2.50 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.62 +0.12 (+4.60%)

As of 08:06 AM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Bicycle Therapeutics NASDAQ:BCYC

$3.89 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.01 (+0.36%)

As of 04:09 AM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

iBio NASDAQ:IBIO

$0.87 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.02 (+1.72%)

As of 09:10 AM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

SAB Biotherapeutics NASDAQ:SABS

$2.98 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.94 -0.04 (-1.34%)

As of 09:14 AM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, SABS, BCYC, and ACIU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, SABS, BCYC, and ACIU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, SABS, BCYC, and ACIU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, SABS, BCYC, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

Bicycle Therapeutics NASDAQ:BCYC

iBio NASDAQ:IBIO

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, SABS, BCYC, and ACIU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, SABS, BCYC, and ACIU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, SABS, BCYC, and ACIU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, SABS, BCYC, and ACIU Company Descriptions

AC Immune NASDAQ:ACIU

Bicycle Therapeutics NASDAQ:BCYC

iBio NASDAQ:IBIO

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools